Skip to main content
Jordan B. King

Jordan B. King, PharmD, MSCI

Languages spoken: Portuguese, English

Academic Information

Departments Primary - Population Health Sciences

Academic Office Information

Dr. King is currently an Assistant Professor of Population Health Sciences in the Division of Health System Innovation and Research and an Affiliate Investigator at the Institute for Health Research at Kaiser Permanente Colorado. His research is focused on improving medication use, particularly through the use of pharmacist-led health services. In particular, his lab has focused on anticoagulant management strategies, antihypertensive medication use and outcomes, and helping patients make unbiased decisions after experiencing statin-related side effects. His research has been published in the New England Journal of Medicine, The Journal of the American College of Cardiology, Diabetes Care, Hypertension, and JAMA Cardiology. He has been previously funded as a Principal Investigator by an AHRQ R18 (R18HS026156) and is currently funded by an NHLBI R01 (R01HL157439). He is also an NIH Loan Repayment Program awardee.

Dr. King received his Doctor of Pharmacy degree from Roseman University of Health Sciences, and his Masters of Science in Clinical Investigation from the University of Utah School of Medicine. He completed his post-doctoral research fellowship in Health Economics and Outcomes Research in the Pharmacotherapy Outcomes Research Center at the University of Utah College of Pharmacy.

Education History

Fellowship University of Utah
University of Utah School of Medicine
Doctoral Training Roseman University of Health Sciences, College of Pharmacy

Selected Publications

Journal Article

  1. King JB, Berchie RO, Derington CG, Marcum ZA, Scharfstein DO, Greene TH, Herrick JS, Jacobs JA, Zheutlin AR, Bress AP, Cohen JB (2023). New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT. J Am Heart Assoc, 12(17), e030311.
  2. King JB, Derington CG, Herrick JS, Jacobs JA, Zheutlin AR, Conroy MB, Cushman WC, Bress AP (2023). Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial. Hypertension, 80(8), 1749-1758.
  3. Derington CG, Goodrich GK, Xu S, Clark NP, Reynolds K, An J, Witt DM, Smith DH, OKeeffe-Rosetti M, Lang DT, Ho PM, Cheetham TC, Comer AC, King JB (2023). Association of Direct Oral Anticoagulation Management Strategies With Clinical Outcomes for Adults With Atrial Fibrillation. JAMA Netw Open, 6(7), e2321971.
  4. Derington CG, Bress AP, Herrick JS, Jacobs JA, Zheutlin AR, Berchie RO, Conroy MB, Cushman WC, King JB (2023). Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed-Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020. J Am Heart Assoc, e028573.
  5. Ghazi L, Shen J, Ying J, Derington CG, Cohen JB, Marcum ZA, Herrick JS, King JB, Cheung AK, Williamson JD, Pajewski NM, Bryan N, Supiano M, Sonnen J, Weintraub WS, Greene TH, Bress AP (2023). Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit: A Secondary Analysis of the SPRINT Randomized Clinical Trial. JAMA Netw Open, 6(5), e2314443.
  6. Mangrum JS, Saunders JA, Chaiyakunapruk N, Witt DM, King JB (2023). A scoping review of direct oral anticoagulant ambulatory management practices. J Thromb Thrombolysis.
  7. Jacobs JA, Addo DK, Zheutlin AR, Derington CG, Essien UR, Navar AM, Hernandez I, Lloyd-Jones DM, King JB, Rao S, Herrick JS, Bress AP, Pandey A (2023). Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol.
  8. Derington CG, Bress AP, Moran AE, Weintraub WS, Herrick JS, Cushman WC, Kronish IM, Stults B, Shimbo D, Muntner P, Greene T, Bates JT, Chang TI, Katz LA, Rehman SU, Roumie CL, Tamariz L, King JB (2022). Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial. Hypertension, 80(3), 590-597.
  9. Green MB, Shimbo D, Schwartz JE, Bress AP, King JB, Muntner P, Sheppard JP, McManus RJ, Kohli-Lynch CN, Zhang Y, Shea S, Moran AE, Bellows BK (2022). Cost-Effectiveness of Masked Hypertension Screening and Treatment in US Adults With Suspected Masked Hypertension: A Simulation Study. Am J Hypertens, 35(8), 752-762.
  10. Cohen JB, Marcum ZA, Zhang C, Derington CG, Greene TH, Ghazi L, Herrick JS, King JB, Cheung AK, Bryan N, Supiano MA, Sonnen JA, Weintraub WS, Scharfstein D, Williamson J, Pajewski NM, Bress AP, Systolic Blood Pressure Intervention Trial SPRINT Research Group (2022). Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Netw Open, 5(7), e2220680.
  11. Bellows BK, Xu J, Sheppard JP, Schwartz JE, Shimbo D, Muntner P, McManus RJ, Moran AE, Bryant KB, Cohen LP, Bress AP, King JB, Shikany JM, Green BB, Yano Y, Clark D, Zhang Y (2021). Predicting Out-of-Office Blood Pressure in a Diverse US Population. Am J Hypertens, 35(6), 533-542.
  12. Zheutlin AR, Derington CG, King JB, Berchie RO, Herrick JS, Dixon DL, Cohen JB, Shimbo D, Kronish IM, Saseen JJ, Muntner P, Moran AE, Bress AP (2021). Factors associated with antihypertensive monotherapy among US adults with treated hypertension and uncontrolled blood pressure overall and by race/ethnicity, National Health and Nutrition Examination Survey 2013-2018. Am Heart J, 248, 150-159.
  13. Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, King JB, Bellows BK, Tajeu GS, Derington CG, Johnson J, Andrade K, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P (2022). Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open, 5(2), e2148172.
  14. Zheutlin AR, Mondesir FL, Derington CG, King JB, Zhang C, Cohen JB, Berlowitz DR, Anstey DE, Cushman WC, Greene TH, Ogedegbe O, Bress AP (2022). Analysis of Therapeutic Inertia and Race and Ethnicity in the Systolic Blood Pressure Intervention Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open, 5(1), e2143001.
  15. Marcum ZA, Cohen JB, Zhang C, Derington CG, Greene TH, Ghazi L, Herrick JS, King JB, Cheung AK, Bryan N, Supiano MA, Sonnen JA, Weintraub WS, Williamson J, Pajewski NM, Bress AP, Systolic Blood Pressure Intervention Trial SPRINT Research Group (2022). Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment. JAMA Netw Open, 5(1), e2145319.
  16. King JB, Pinheiro LC, Bryan Ringel J, Bress AP, Shimbo D, Muntner P, Reynolds K, Cushman M, Howard G, Manly JJ, Safford MM (2021). Multiple Social Vulnerabilities to Health Disparities and Hypertension and Death in the REGARDS Study. Hypertension, 79(1), 196-206.
  17. Mohanty AF, Levitan EB, King JB, Dodson JA, Vardeny O, Cook J, Herrick JS, He T, Patterson OV, Alba PR, Russo PA, Obi EN, Choi ME, Fang JC, Bress AP (2021). Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction. J Am Heart Assoc, 10(20), e020474.
  18. Colvin CL, Poudel B, Bress AP, Derington CG, King JB, Wen Y, Chen L, Bittner V, Brown TM, Monda KL, Mues KE, Rosenson RS, Jackson EA, Muntner P, Colantonio LD (2021). Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction. J Clin Lipidol, 15(5), 665-673.
  19. Bellows BK, Zhang Y, Zhang Z, Lloyd-Jones DM, Bress AP, King JB, Kolm P, Cushman WC, Johnson KC, Tamariz L, Oelsner EC, Shea S, Newman AB, Ives DG, Couper D, Moran AE, Weintraub WS (2021). Estimating Systolic Blood Pressure Intervention Trial Participant Posttrial Survival Using Pooled Epidemiologic Cohort Data. J Am Heart Assoc, 10(10), e020361.
  20. Li S, Schwartz JE, Shimbo D, Muntner P, Shikany JM, Booth JN 3rd, Allen NB, Jaeger BC, Bress AP, King JB, Clark D 3rd, Butler KR, Correa A, Moran AE, Bellows BK, Zhang Y (2021). Estimated Prevalence of Masked Asleep Hypertension in US Adults. JAMA Cardiol, 6(5), 568-573.
  21. Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress AP (2021). Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS One, 16(4), e0248080.
  22. Derington CG, Colantonio LD, Herrick JS, Cook J, King JB, Rosenson RS, Poudel B, Monda KL, Navar AM, Mues KE, Stevens VW, Nelson RE, Vanneman ME, Muntner P, Bress AP (2021). Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. J Am Heart Assoc, 10(8), e019254.
  23. Caffiero NA, Nickman NA, Drews FA, King JB, Moorman K, Tyler LS (2020). Reduction of phone interruptions post implementation of a central call center in community pharmacies of an academic health system. Am J Health Syst Pharm, 78(2), 113-121.
  24. Derington CG, King JB, Delate T, Botts SR, Kroehl M, Kao DP, Trinkley KE (2020). Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. PLoS One, 15(12), e0243371.
  25. Delate T, Charlu M, Zhu S, Pai A, Clark NP, Witt DM, King JM, King JB (2020). Temporal trends in first-line outpatient anticoagulation treatment for cancer-associated venous thromboembolism. Thromb Res, 196, 367-370.
  26. Colvin CL, King JB, Oparil S, Wright JT Jr, Ogedegbe G, Mohanty A, Hardy ST, Huang L, Hess R, Muntner P, Bress A (2020). Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report. JAMA Netw Open, 3(11), e2025127.
  27. Shokoohi H, Boniface KS, Loesche MA, Duggan NM, King JB (2019). Development of a nomogram to predict small bowel obstruction using point-of-care ultrasound in the emergency department. Am J Emerg Med, 38(11), 2356-2360.
  28. An J, Derington CG, Luong T, Olson KL, King JB, Bress AP, Jackevicius CA (2020). Fixed-Dose Combination Medications for Treating Hypertension: A Review of Effectiveness, Safety, and Challenges. Curr Hypertens Rep, 22(11), 95.
  29. Jones AE, King JB, Kim K, Witt DM (2020). The role of clinical pharmacy anticoagulation services in direct oral anticoagulant monitoring. J Thromb Thrombolysis, 50(3), 739-745.
  30. Kuye R, Riggs C, King J, Heilmann R, Kurz D, Milchak J (2020). Thyroid Stimulating Hormone Stability in Patients Prescribed Synthetic or Desiccated Thyroid Products: A Retrospective Study. Ann Fam Med.
  31. Bryant KB, Sheppard JP, Ruiz-Negrn N, Kronish IM, Fontil V, King JB, Pletcher MJ, Bibbins-Domingo K, Moran AE, McManus RJ, Bellows BK (2020). Impact of Self-Monitoring of Blood Pressure on Processes of Hypertension Care and Long-Term Blood Pressure Control. J Am Heart Assoc, 9(15), e016174.
  32. Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, Muntner P, Moran AE, Bress AP (2020). Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016. Hypertension, 75(4), 973-981.
  33. Boniface KS, King JB, LeSaux MA, Haciski SC, Shokoohi H (2019). Diagnostic Accuracy and Time-Saving Effects of Point-of-Care Ultrasonography in Patients With Small Bowel Obstruction: A Prospective Study. Ann Emerg Med, 75(2), 246-256.
  34. Pajewski NM, Berlowitz DR, Bress AP, Callahan KE, Cheung AK, Fine LJ, Gaussoin SA, Johnson KC, King J, Kitzman DW, Kostis JB, Lerner AJ, Lewis CE, Oparil S, Rahman M, Reboussin DM, Rocco MV, Snyder JK, Still C, Supiano MA, Wadley VG, Whelton PK, Wright JT Jr, Williamson JD (2019). Intensive vs Standard Blood Pressure Control in Adults 80 Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial. J Am Geriatr Soc, 68(3), 496-504.
  35. Derington CG, King JB, Bryant KB, McGee BT, Moran AE, Weintraub WS, Bellows BK, Bress AP (2019). Cost-Effectiveness and Challenges of Implementing Intensive Blood Pressure Goals and Team-Based Care. Curr Hypertens Rep, 21(12), 91.
  36. Mohanty AF, Levitan EB, Dodson JA, Vardeny O, King JB, LaFleur J, He T, Patterson OV, Alba PR, Russo PA, Choi ME, Bress AP (2019). Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan. Circ Heart Fail, 12(11), e005691.
  37. Owlia M, Dodson JA, King JB, Derington CG, Herrick JS, Sedlis SP, Crook J, DuVall SL, LaFleur J, Nelson R, Patterson OV, Shah RU, Bress AP (2019). Angina Severity, Mortality, and Healthcare Utilization Among Veterans With Stable Angina. J Am Heart Assoc, 8(15), e012811.
  38. Derington CG, Gums TH, Bress AP, Herrick JS, Greene TH, Moran AE, Weintraub WS, Kronish IM, Morisky DE, Trinkley KE, Saseen JJ, Reynolds K, Bates JT, Berlowitz DR, Chang TI, Chonchol M, Cushman WC, Foy CG, Herring CT, Katz LA, Krousel-Wood M, Pajewski NM, Tamariz L, King JB, SPRINT Research Group (2019). Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT. Hypertension, HYPERTENSIONAHA11912907.
  39. Bellows BK, Ruiz-Negrn N, Bibbins-Domingo K, King JB, Pletcher MJ, Moran AE, Fontil V (2019). Clinic-Based Strategies to Reach United States Million Hearts 2022 Blood Pressure Control Goals. Circ Cardiovasc Qual Outcomes, 12(6), e005624.
  40. Chamberlain AM, Gong Y, Shaw KM, Bian J, Song WL, Linton MF, Fonseca V, Price-Haywood E, Guhl E, King JB, Shah RU, Puro J, Shenkman E, Pawloski PA, Margolis KL, Hernandez AF, Cooper-DeHoff RM (2019). PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network. J Am Heart Assoc, 8(9), e011246.
  41. Ruiz-Negrn N, Menon J, King JB, Ma J, Bellows BK (2019). Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review. Pharmacoeconomics, 37(5), 669-688.
  42. Bress AP, King JB (2018). Optimizing Medical Therapy in Chronic Worsening HFrEF: A Long Way to Go. J Am Coll Cardiol, 73(8), 945-947.
  43. Chelu MG, King JB, Kholmovski EG, Ma J, Gal P, Marashly Q, AlJuaid MA, Kaur G, Silver MA, Johnson KA, Suksaranjit P, Wilson BD, Han FT, Elvan A, Marrouche NF (2018). Atrial Fibrosis by Late Gadolinium Enhancement Magnetic Resonance Imaging and Catheter Ablation of Atrial Fibrillation: 5-Year Follow-Up Data. J Am Heart Assoc, 7(23), e006313.
  44. Bress AP, Dodson JA, King JB, Sauer BC, Reese T, Crook J, Radwanski P, Knippenberg K, Greene T, Nelson RE, Munger MA, Weintraub WS, LaFleur J (2018). Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris. Am J Cardiol, 122(11), 1809-1816.
  45. Hawkins KL, King J, Delate T, Martinez K, McCool K, Clark NP (2018). Pharmacy Technician Management of Stable, In-Range INRs Within a Clinical Pharmacy Anticoagulation Service. J Manag Care Spec Pharm, 24(11), 1130-1137.
  46. King J, Bress A, Bellows B (2017). Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction. Ann Intern Med, 166(8), 606-607.
  47. Shokoohi H, Berry GW, Shahkolahi M, King JM, King JB, Salimian M, Poshtmashad A, Pourmand A (2016). The diagnostic utility of sonographic carotid flow time in determining volume responsiveness. J Crit Care, 38, 231-235.